Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of DNL310 in Pediatric Participants With Hunter Syndrome (MPS II)
2023-508619-22-00Phase 2Completed
- Sponsor
- Denali Therapeutics Inc.
- Start
- Jun 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, open-label trial of tividenofusp alfa in mucopolysaccharidosis type 2 (5 cohorts), sponsored by Denali Therapeutics Inc. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Incidence and severity of infusion-related reactions and 2 more. Started Jun 2024; status: completed.
02
Drugs
tividenofusp alfa
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on 2023-508619-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508619-22-00.